Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ...

Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group"), today announced that the U.S. Food and Drug Administration (FDA ...

New PDUFA Target Action Date of January 14, 2026 set by FDAMIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc.

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences (Zydus Group), today announced that the U.S. Food and Drug Administration (FDA) has ...

("GenSci"), RTW Investments, LP ("RTW"), and Yarrow Bioscience, Inc. ("Yarrow") today announced an exclusive global ex-China license agreement for GS-098, a clinical-stage, first-in-class, humanized ...

After its disastrous phase III eye disease trials, Opthea will repurpose its lead asset to treat a rare lung disease the ...

Some of our most promising biotechs have taken part in a pre yuletide rush of clinical trial updates – and there is much to ...

EVENTS FRIDAY Community Development and Veterans Services Outreach Event — 2-3 p.m., Cheyenne Mountain State Park, Visitor Center, 410 JL Ranch Heights, park fee is waived. Registration: ...

U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults ...

GenSci and RTW Investments announce exclusive global ex-China license agreement for GS-098: Shanghai Thursday, December 18, 2025, 17:00 Hrs [IST] Shanghai Scizeng Medical Technolo ...